Expansion of Fcγ Receptor IIIa–Positive Macrophages, Ficolin 1–Positive Monocyte‐Derived Dendritic Cells, and Plasmacytoid Dendritic Cells Associated With Severe Skin Disease in Systemic Sclerosis
Objective In this study, we sought a comprehensive understanding of myeloid cell types driving fibrosis in diffuse cutaneous systemic sclerosis (dcSSc) skin. Methods We analyzed the transcriptomes of 2,465 myeloid cells from skin biopsy specimens from 12 dcSSc patients and 10 healthy control subject...
Saved in:
Published in | Arthritis & rheumatology (Hoboken, N.J.) Vol. 74; no. 2; pp. 329 - 341 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Boston, USA
Wiley Periodicals, Inc
01.02.2022
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Objective
In this study, we sought a comprehensive understanding of myeloid cell types driving fibrosis in diffuse cutaneous systemic sclerosis (dcSSc) skin.
Methods
We analyzed the transcriptomes of 2,465 myeloid cells from skin biopsy specimens from 12 dcSSc patients and 10 healthy control subjects using single‐cell RNA sequencing. Monocyte‐derived dendritic cells (mo‐DCs) were assessed using immunohistochemical staining and immunofluorescence analyses targeting ficolin‐1 (FCN‐1).
Results
A t‐distributed stochastic neighbor embedding analysis of single‐cell transcriptome data revealed 12 myeloid cell clusters, 9 of which paralleled previously described healthy control macrophage/DC clusters, and 3 of which were dcSSc‐specific myeloid cell clusters. One SSc‐associated macrophage cluster, highly expressing Fcγ receptor IIIA, was suggested on pseudotime analysis to be derived from normal CCR1+ and MARCO+ macrophages. A second SSc‐associated myeloid population highly expressed monocyte markers FCN‐1, epiregulin, S100A8, and S100A9, but was closely related to type 2 conventional DCs on pseudotime analysis and identified as mo‐DCs. Mo‐DCs were associated with more severe skin disease. Proliferating macrophages and plasmacytoid DCs were detected almost exclusively in dcSSc skin, the latter clustering with B cells and apparently derived from lymphoid progenitors.
Conclusion
Transcriptional signatures in these and other myeloid populations indicate innate immune system activation, possibly through Toll‐like receptors and highly up‐regulated chemokines. However, the appearance and activation of myeloid cells varies between patients, indicating potential differences in the underlying pathogenesis and/or temporal disease activity in dcSSc. |
---|---|
AbstractList | ObjectiveIn this study, we sought a comprehensive understanding of myeloid cell types driving fibrosis in diffuse cutaneous systemic sclerosis (dcSSc) skin.MethodsWe analyzed the transcriptomes of 2,465 myeloid cells from skin biopsy specimens from 12 dcSSc patients and 10 healthy control subjects using single‐cell RNA sequencing. Monocyte‐derived dendritic cells (mo‐DCs) were assessed using immunohistochemical staining and immunofluorescence analyses targeting ficolin‐1 (FCN‐1).ResultsA t‐distributed stochastic neighbor embedding analysis of single‐cell transcriptome data revealed 12 myeloid cell clusters, 9 of which paralleled previously described healthy control macrophage/DC clusters, and 3 of which were dcSSc‐specific myeloid cell clusters. One SSc‐associated macrophage cluster, highly expressing Fcγ receptor IIIA, was suggested on pseudotime analysis to be derived from normal CCR1+ and MARCO+ macrophages. A second SSc‐associated myeloid population highly expressed monocyte markers FCN‐1, epiregulin, S100A8, and S100A9, but was closely related to type 2 conventional DCs on pseudotime analysis and identified as mo‐DCs. Mo‐DCs were associated with more severe skin disease. Proliferating macrophages and plasmacytoid DCs were detected almost exclusively in dcSSc skin, the latter clustering with B cells and apparently derived from lymphoid progenitors.ConclusionTranscriptional signatures in these and other myeloid populations indicate innate immune system activation, possibly through Toll‐like receptors and highly up‐regulated chemokines. However, the appearance and activation of myeloid cells varies between patients, indicating potential differences in the underlying pathogenesis and/or temporal disease activity in dcSSc. Objective In this study, we sought a comprehensive understanding of myeloid cell types driving fibrosis in diffuse cutaneous systemic sclerosis (dcSSc) skin. Methods We analyzed the transcriptomes of 2,465 myeloid cells from skin biopsy specimens from 12 dcSSc patients and 10 healthy control subjects using single‐cell RNA sequencing. Monocyte‐derived dendritic cells (mo‐DCs) were assessed using immunohistochemical staining and immunofluorescence analyses targeting ficolin‐1 (FCN‐1). Results A t‐distributed stochastic neighbor embedding analysis of single‐cell transcriptome data revealed 12 myeloid cell clusters, 9 of which paralleled previously described healthy control macrophage/DC clusters, and 3 of which were dcSSc‐specific myeloid cell clusters. One SSc‐associated macrophage cluster, highly expressing Fcγ receptor IIIA, was suggested on pseudotime analysis to be derived from normal CCR1+ and MARCO+ macrophages. A second SSc‐associated myeloid population highly expressed monocyte markers FCN‐1, epiregulin, S100A8, and S100A9, but was closely related to type 2 conventional DCs on pseudotime analysis and identified as mo‐DCs. Mo‐DCs were associated with more severe skin disease. Proliferating macrophages and plasmacytoid DCs were detected almost exclusively in dcSSc skin, the latter clustering with B cells and apparently derived from lymphoid progenitors. Conclusion Transcriptional signatures in these and other myeloid populations indicate innate immune system activation, possibly through Toll‐like receptors and highly up‐regulated chemokines. However, the appearance and activation of myeloid cells varies between patients, indicating potential differences in the underlying pathogenesis and/or temporal disease activity in dcSSc. In this study, we sought a comprehensive understanding of myeloid cell types driving fibrosis in diffuse cutaneous systemic sclerosis (dcSSc) skin.OBJECTIVEIn this study, we sought a comprehensive understanding of myeloid cell types driving fibrosis in diffuse cutaneous systemic sclerosis (dcSSc) skin.We analyzed the transcriptomes of 2,465 myeloid cells from skin biopsy specimens from 12 dcSSc patients and 10 healthy control subjects using single-cell RNA sequencing. Monocyte-derived dendritic cells (mo-DCs) were assessed using immunohistochemical staining and immunofluorescence analyses targeting ficolin-1 (FCN-1).METHODSWe analyzed the transcriptomes of 2,465 myeloid cells from skin biopsy specimens from 12 dcSSc patients and 10 healthy control subjects using single-cell RNA sequencing. Monocyte-derived dendritic cells (mo-DCs) were assessed using immunohistochemical staining and immunofluorescence analyses targeting ficolin-1 (FCN-1).A t-distributed stochastic neighbor embedding analysis of single-cell transcriptome data revealed 12 myeloid cell clusters, 9 of which paralleled previously described healthy control macrophage/DC clusters, and 3 of which were dcSSc-specific myeloid cell clusters. One SSc-associated macrophage cluster, highly expressing Fcγ receptor IIIA, was suggested on pseudotime analysis to be derived from normal CCR1+ and MARCO+ macrophages. A second SSc-associated myeloid population highly expressed monocyte markers FCN-1, epiregulin, S100A8, and S100A9, but was closely related to type 2 conventional DCs on pseudotime analysis and identified as mo-DCs. Mo-DCs were associated with more severe skin disease. Proliferating macrophages and plasmacytoid DCs were detected almost exclusively in dcSSc skin, the latter clustering with B cells and apparently derived from lymphoid progenitors.RESULTSA t-distributed stochastic neighbor embedding analysis of single-cell transcriptome data revealed 12 myeloid cell clusters, 9 of which paralleled previously described healthy control macrophage/DC clusters, and 3 of which were dcSSc-specific myeloid cell clusters. One SSc-associated macrophage cluster, highly expressing Fcγ receptor IIIA, was suggested on pseudotime analysis to be derived from normal CCR1+ and MARCO+ macrophages. A second SSc-associated myeloid population highly expressed monocyte markers FCN-1, epiregulin, S100A8, and S100A9, but was closely related to type 2 conventional DCs on pseudotime analysis and identified as mo-DCs. Mo-DCs were associated with more severe skin disease. Proliferating macrophages and plasmacytoid DCs were detected almost exclusively in dcSSc skin, the latter clustering with B cells and apparently derived from lymphoid progenitors.Transcriptional signatures in these and other myeloid populations indicate innate immune system activation, possibly through Toll-like receptors and highly up-regulated chemokines. However, the appearance and activation of myeloid cells varies between patients, indicating potential differences in the underlying pathogenesis and/or temporal disease activity in dcSSc.CONCLUSIONTranscriptional signatures in these and other myeloid populations indicate innate immune system activation, possibly through Toll-like receptors and highly up-regulated chemokines. However, the appearance and activation of myeloid cells varies between patients, indicating potential differences in the underlying pathogenesis and/or temporal disease activity in dcSSc. In this study, we sought a comprehensive understanding of myeloid cell types driving fibrosis in diffuse cutaneous systemic sclerosis (dcSSc) skin. We analyzed the transcriptomes of 2,465 myeloid cells from skin biopsy specimens from 12 dcSSc patients and 10 healthy control subjects using single-cell RNA sequencing. Monocyte-derived dendritic cells (mo-DCs) were assessed using immunohistochemical staining and immunofluorescence analyses targeting ficolin-1 (FCN-1). A t-distributed stochastic neighbor embedding analysis of single-cell transcriptome data revealed 12 myeloid cell clusters, 9 of which paralleled previously described healthy control macrophage/DC clusters, and 3 of which were dcSSc-specific myeloid cell clusters. One SSc-associated macrophage cluster, highly expressing Fcγ receptor IIIA, was suggested on pseudotime analysis to be derived from normal CCR1+ and MARCO+ macrophages. A second SSc-associated myeloid population highly expressed monocyte markers FCN-1, epiregulin, S100A8, and S100A9, but was closely related to type 2 conventional DCs on pseudotime analysis and identified as mo-DCs. Mo-DCs were associated with more severe skin disease. Proliferating macrophages and plasmacytoid DCs were detected almost exclusively in dcSSc skin, the latter clustering with B cells and apparently derived from lymphoid progenitors. Transcriptional signatures in these and other myeloid populations indicate innate immune system activation, possibly through Toll-like receptors and highly up-regulated chemokines. However, the appearance and activation of myeloid cells varies between patients, indicating potential differences in the underlying pathogenesis and/or temporal disease activity in dcSSc. |
Author | Xue, Dan Tabib, Tracy Lafyatis, Robert Khanna, Dinesh Domsic, Robyn T. Morse, Christina Yang, Yi |
Author_xml | – sequence: 1 givenname: Dan surname: Xue fullname: Xue, Dan organization: University of Pittsburgh, Pittsburgh, Pennsylvania, and Xiangya Hospital, Central South University – sequence: 2 givenname: Tracy surname: Tabib fullname: Tabib, Tracy organization: University of Pittsburgh – sequence: 3 givenname: Christina surname: Morse fullname: Morse, Christina organization: University of Pittsburgh – sequence: 4 givenname: Yi surname: Yang fullname: Yang, Yi organization: Xiangya Hospital, Central South University – sequence: 5 givenname: Robyn T. orcidid: 0000-0002-2765-0922 surname: Domsic fullname: Domsic, Robyn T. organization: University of Pittsburgh – sequence: 6 givenname: Dinesh orcidid: 0000-0003-1412-4453 surname: Khanna fullname: Khanna, Dinesh organization: University of Michigan – sequence: 7 givenname: Robert orcidid: 0000-0002-9398-5034 surname: Lafyatis fullname: Lafyatis, Robert email: lafyatis@pitt.edu organization: University of Pittsburgh |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34042322$$D View this record in MEDLINE/PubMed |
BookMark | eNp1ks9uEzEQxleoiJbSAy-ALHEBibT-s95dH6OkgUhFVE0RR8vrTKjL7nqxnba59RGQeBQeA4mH6JMwkORAAV888vy-zyPN9zjb6XwHWfaU0UNGKT8yIR3mrGLiQbbHBS8GklO5s62ZYrvZQYyXFI8qaUHlo2xX5DTHPt_Lvh_f9KaLznfEL8jE_vhGzsBCn3wg0-nU3N1-PfXRJXcF5K2xwfcX5iPEV2TirG9cR9gfhO-8XSW4u_0yhoAvczKGbh6wa8kImgaFppuT08bE1iDp3V8EGcborTMJxR9cuiAzuIIAZPYJfxu7CCYCwXK2iglaVM1sAwEniE-yhwvTRDjY3PvZ-8nx-ejN4OTd6-loeDKwoqrEQNRAeS5oKZksy0LJWlRQ1sqovCxlyctaCsnLRV0LygqjBMfC5IzK3AJYJfazF2vfPvjPS4hJty5anN104JdRcymEYFWuCkSf30Mv_TJ0OJ3mBedKSqkYUs821LJuYa774FoTVnq7JgSO1gAuIMYAC21dMgm3loJxjWZU_8qCxizo31lAxct7iq3pv9iN-7VrYPV_UA_PzteKn-w7xuI |
CitedBy_id | crossref_primary_10_1016_j_celrep_2024_113977 crossref_primary_10_1016_j_mam_2024_101252 crossref_primary_10_1093_rheumatology_keac410 crossref_primary_10_1002_art_42536 crossref_primary_10_3389_fimmu_2024_1430825 crossref_primary_10_1093_rheumatology_keae517 crossref_primary_10_1016_j_isci_2023_106653 crossref_primary_10_1038_s41392_025_02124_y crossref_primary_10_1016_j_lfs_2022_121238 crossref_primary_10_1002_path_5984 crossref_primary_10_1186_s10020_024_01047_8 crossref_primary_10_1186_s12951_023_01921_3 crossref_primary_10_3389_fimmu_2023_1219487 crossref_primary_10_1016_j_jid_2023_09_288 crossref_primary_10_1038_s41577_024_01043_3 crossref_primary_10_1016_j_clindermatol_2024_12_007 crossref_primary_10_1038_s41392_022_01070_3 crossref_primary_10_2147_PTT_S492205 crossref_primary_10_1038_s41467_023_41328_0 crossref_primary_10_1177_25152564241291374 crossref_primary_10_1002_art_43044 crossref_primary_10_31083_j_fbs1504016 crossref_primary_10_3389_fimmu_2022_1051254 crossref_primary_10_1016_j_xcrm_2024_101399 crossref_primary_10_1038_s41392_023_01501_9 crossref_primary_10_1002_art_42247 crossref_primary_10_1007_s12016_023_08969_x crossref_primary_10_1093_rheumatology_keac421 crossref_primary_10_1038_s41592_024_02175_z crossref_primary_10_1093_rheumatology_keae688 crossref_primary_10_1002_art_42662 crossref_primary_10_1152_ajpcell_00813_2024 crossref_primary_10_3390_biomedicines10020316 crossref_primary_10_3390_ijms25179182 crossref_primary_10_1002_ctm2_1545 crossref_primary_10_1038_s41584_022_00864_7 crossref_primary_10_3389_fphar_2022_826839 crossref_primary_10_1097_j_pain_0000000000003106 crossref_primary_10_3389_fmed_2021_822804 crossref_primary_10_1016_j_pharmthera_2025_108807 crossref_primary_10_1016_j_jaut_2023_103097 crossref_primary_10_1097_j_pain_0000000000003107 crossref_primary_10_1097_BOR_0000000000001047 crossref_primary_10_1038_s41584_022_00803_6 crossref_primary_10_3389_fimmu_2023_1240800 crossref_primary_10_1016_j_autrev_2024_103637 crossref_primary_10_1002_art_42380 crossref_primary_10_3389_fimmu_2024_1452801 |
Cites_doi | 10.1038/s41590-018-0136-9 10.1038/s41467-021-24607-6 10.1002/art.38288 10.1016/j.jid.2017.09.045 10.1016/S0140-6736(17)30933-9 10.1038/nbt.2859 10.1002/art.40455 10.1146/annurev-immunol-051116-052215 10.3389/fimmu.2019.01222 10.1038/s41467-019-09683-z 10.1016/j.ajpath.2010.08.003 10.1002/art.39289 10.1038/jid.2011.472 10.1038/s41577-018-0029-z 10.1084/jem.20190811 10.1002/art.39287 10.1136/annrheumdis-2018-214865 10.1186/ar3066 10.1126/scitranslmed.aam8458 10.1371/journal.pone.0002696 10.1038/jid.2010.200 10.1038/s41592-019-0619-0 10.1016/j.imlet.2017.11.003 10.1111/imm.12888 10.1183/13993003.02441-2018 10.1056/NEJMoa1114576 10.1007/s11926-019-0831-z 10.1136/ard.2010.132464 10.1038/nbt.4096 10.1002/art.22382 10.1371/journal.pone.0001452 10.1126/science.aah4573 10.1189/jlb.1A0314-170R 10.1172/jci.insight.98850 10.1159/000163933 10.1136/annrheumdis-2012-202814 10.1186/ar4598 10.1016/j.jdermsci.2019.11.012 10.1089/wound.2017.0732 10.1016/S0140-6736(16)00232-4 |
ContentType | Journal Article |
Copyright | 2021, American College of Rheumatology 2021, American College of Rheumatology. 2022 American College of Rheumatology |
Copyright_xml | – notice: 2021, American College of Rheumatology – notice: 2021, American College of Rheumatology. – notice: 2022 American College of Rheumatology |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QL 7QP 7T5 7TM 7U7 C1K H94 K9. 7X8 |
DOI | 10.1002/art.41813 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Immunology Abstracts Nucleic Acids Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Toxicology Abstracts Bacteriology Abstracts (Microbiology B) Nucleic Acids Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Calcium & Calcified Tissue Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | Toxicology Abstracts MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2326-5205 |
EndPage | 341 |
ExternalDocumentID | 34042322 10_1002_art_41813 ART41813 |
Genre | article Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: China Scholarship Council (CSC) funderid: 201706370258 – fundername: National Institute of Arthritis and Musculoskeletal and Skin Diseases funderid: P50AR060780 – fundername: NIAMS NIH HHS grantid: R61 AR076819 – fundername: NIAMS NIH HHS grantid: P50 AR060780 – fundername: NIAMS NIH HHS grantid: P50AR060780 – fundername: China Scholarship Council (CSC) grantid: 201706370258 |
GroupedDBID | 0R~ 1OC 24P 33P 3SF 4.4 52O 52U 52V 53G 5VS AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAQQT AASGY AAWTL AAXRX AAYCA AAZKR ABCUV ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACRPL ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZFZN AZVAB BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 DCZOG DIK DRFUL DRMAN DRSTM EBS EJD EMOBN EX3 F00 FUBAC G-S G.N GODZA HGLYW KBYEO LATKE LEEKS LH4 LITHE LOXES LUTES LW6 LYRES MEWTI MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM NF~ O66 O9- OK1 OVD P2W PQQKQ QB0 ROL SUPJJ SV3 TEORI V9Y WBKPD WHWMO WIH WIJ WIK WOHZO WVDHM WXSBR YCJ AAFWJ AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY CGR CUY CVF ECM EIF NPM 7QL 7QP 7T5 7TM 7U7 C1K H94 K9. 7X8 |
ID | FETCH-LOGICAL-c3883-3be02430751577695b38e7b9a94775727b53527fbb3016a932b30a41054ceec93 |
ISSN | 2326-5191 2326-5205 |
IngestDate | Fri Jul 11 09:31:46 EDT 2025 Fri Jul 25 12:19:30 EDT 2025 Mon Jul 21 06:02:22 EDT 2025 Tue Jul 01 00:56:03 EDT 2025 Thu Apr 24 23:08:26 EDT 2025 Wed Jan 22 16:26:24 EST 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
License | 2021, American College of Rheumatology. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c3883-3be02430751577695b38e7b9a94775727b53527fbb3016a932b30a41054ceec93 |
Notes | Supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH (grant 2P50‐AR‐060780) and by an unrestricted grant from Pfizer. Dr. Xue's work was supported by the China Scholarship Council (grant 201706370258). Dr. Domsic has received consulting fees from Eicos Sciences and Boehringer‐Ingelheim (less than $10,000 each). Dr. Khanna has received consulting fees from Actelion, Acceleron, Bristol Myers Squibb, Blade Therapeutics, Bayer, ChemomAB, Cytori, Celgene, Curzion, Corbus Pharmaceuticals, CSL Behring, GlaxoSmithKline, Genentech, Mitsubishi Tanabe Pharma Development America, Sanofi‐Aventis, and UCB (less than $10,000 each) and from Eicos Sciences, Horizon, and Boehringer Ingelheim (more than $10,000 each), has received grant support from Bristol Myers Squibb, Pfizer, Bayer, and Horizon, and owns stock or stock options in Eicos Sciences and CiviBio Pharma. Dr. Lafyatis has received consulting fees from Bristol Myers Squibb, Formation, Sanofi, Biocon, Boehringer‐Mannheim, Merck, and Genentech/Roche (less than $10,000 each) and research grants from Corbus, Formation, Elpidera, Regeneron, Pfizer, and Kiniksa. No other disclosures relevant to this article were reported. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-2765-0922 0000-0002-9398-5034 0000-0003-1412-4453 |
OpenAccessLink | https://hdl.handle.net/2027.42/171515 |
PMID | 34042322 |
PQID | 2622955591 |
PQPubID | 946334 |
PageCount | 13 |
ParticipantIDs | proquest_miscellaneous_2533318496 proquest_journals_2622955591 pubmed_primary_34042322 crossref_citationtrail_10_1002_art_41813 crossref_primary_10_1002_art_41813 wiley_primary_10_1002_art_41813_ART41813 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | February 2022 2022-02-00 20220201 |
PublicationDateYYYYMMDD | 2022-02-01 |
PublicationDate_xml | – month: 02 year: 2022 text: February 2022 |
PublicationDecade | 2020 |
PublicationPlace | Boston, USA |
PublicationPlace_xml | – name: Boston, USA – name: United States – name: Atlanta |
PublicationTitle | Arthritis & rheumatology (Hoboken, N.J.) |
PublicationTitleAlternate | Arthritis Rheumatol |
PublicationYear | 2022 |
Publisher | Wiley Periodicals, Inc Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Periodicals, Inc – name: Wiley Subscription Services, Inc |
References | 2010; 12 2017; 6 2019; 54 2019; 10 2015; 97 2019; 78 2017; 390 2019; 16 2016; 387 1992; 19 2014; 370 2008; 3 2007; 56 2017; 356 2011; 178 2014; 66 2019; 154635 1995; 63 2015; 67 2018; 19 2018; 18 2018; 154 2018; 3 2012; 132 2018; 195 2021; 12 2020; 97 2018; 138 2019; 21 2011; 70 2017; 35 2018; 70 2014; 16 2020; 217 2010; 130 2014; 73 2018; 10 2014; 32 2018; 36 e_1_2_7_6_1 e_1_2_7_4_1 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_8_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_18_1 e_1_2_7_17_1 e_1_2_7_16_1 e_1_2_7_40_1 e_1_2_7_2_1 e_1_2_7_15_1 Skaug B (e_1_2_7_30_1) 2019; 154635 e_1_2_7_41_1 e_1_2_7_14_1 e_1_2_7_42_1 e_1_2_7_13_1 e_1_2_7_43_1 e_1_2_7_12_1 e_1_2_7_11_1 e_1_2_7_10_1 e_1_2_7_26_1 Ishikawa O (e_1_2_7_5_1) 1992; 19 e_1_2_7_27_1 e_1_2_7_28_1 e_1_2_7_29_1 e_1_2_7_25_1 e_1_2_7_31_1 e_1_2_7_24_1 e_1_2_7_32_1 e_1_2_7_23_1 e_1_2_7_33_1 e_1_2_7_22_1 e_1_2_7_34_1 e_1_2_7_21_1 e_1_2_7_35_1 e_1_2_7_20_1 e_1_2_7_36_1 e_1_2_7_37_1 e_1_2_7_38_1 e_1_2_7_39_1 35644033 - Arthritis Rheumatol. 2022 Oct;74(10):1721-1722 |
References_xml | – volume: 390 start-page: 1685 year: 2017 end-page: 99 article-title: Systemic sclerosis [review] publication-title: Lancet – volume: 10 start-page: 1731 year: 2019 article-title: CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9‐mediated interferon‐α production in systemic sclerosis publication-title: Nat Commun – volume: 12 year: 2021 article-title: Myofibroblast transcriptome indicates SFRP2(hi) fibroblast progenitors in systemic sclerosis skin publication-title: Nat Commun – volume: 6 start-page: 356 year: 2017 end-page: 69 article-title: Toll‐like receptor‐4 signaling drives persistent fibroblast activation and prevents fibrosis resolution in scleroderma [review] publication-title: Adv Wound Care (New Rochelle) – volume: 16 start-page: R136 year: 2014 article-title: Chronic Toll‐like receptor 4 stimulation in skin induces inflammation, macrophage activation, transforming growth factor β signature gene expression, and fibrosis publication-title: Arthritis Res Ther – volume: 217 year: 2020 article-title: Re‐evaluation of human BDCA‐2+ DC during acute sterile skin inflammation publication-title: J Exp Med – volume: 130 start-page: 2583 year: 2010 end-page: 93 article-title: Poly(I:C) drives type I IFN‐ and TGFβ‐mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis publication-title: J Invest Dermatol – volume: 56 start-page: 1010 year: 2007 end-page: 20 article-title: A macrophage marker, Siglec‐1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll‐like receptor agonists publication-title: Arthritis Rheum – volume: 10 year: 2018 article-title: Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8 publication-title: Sci Transl Med – volume: 66 start-page: 714 year: 2014 end-page: 25 article-title: Association of interferon‐ and transforming growth factor β–regulated genes and macrophage activation with systemic sclerosis–related progressive lung fibrosis publication-title: Arthritis Rheumatol – volume: 3 year: 2008 article-title: Molecular subsets in the gene expression signatures of scleroderma skin publication-title: PloS One – volume: 10 start-page: 1222 year: 2019 article-title: What makes a pDC: recent advances in understanding plasmacytoid DC development and heterogeneity [review] publication-title: Front Immunol – volume: 154 start-page: 3 year: 2018 end-page: 20 article-title: Human dendritic cell subsets: an update [review] publication-title: Immunology – volume: 3 year: 2018 article-title: TLR4‐dependent fibroblast activation drives persistent organ fibrosis in skin and lung publication-title: JCI Insight – volume: 73 start-page: 1864 year: 2014 end-page: 72 article-title: Global chemokine expression in systemic sclerosis (SSc): CCL19 expression correlates with vascular inflammation in SSc skin publication-title: Ann Rheum Dis – volume: 16 start-page: 1289 year: 2019 end-page: 96 article-title: Fast, sensitive and accurate integration of single‐cell data with Harmony publication-title: Nat Methods – volume: 138 start-page: 802 year: 2018 end-page: 10 article-title: SFRP2/DPP4 and FMO1/LSP1 define major fibroblast populations in human skin publication-title: J Invest Dermatol – volume: 19 start-page: 711 year: 2018 end-page: 22 article-title: Distinct progenitor lineages contribute to the heterogeneity of plasmacytoid dendritic cells publication-title: Nat Immunol – volume: 18 start-page: 545 year: 2018 end-page: 58 article-title: IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy [review] publication-title: Nat Rev Immunol – volume: 21 start-page: 31 year: 2019 article-title: Macrophages in systemic sclerosis: novel insights and therapeutic implications [review] publication-title: Curr Rheumatol Rep – volume: 356 year: 2017 article-title: Single‐cell RNA‐seq reveals new types of human blood dendritic cells, monocytes, and progenitors publication-title: Science – volume: 3 year: 2008 article-title: Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? publication-title: PloS One – volume: 370 start-page: 433 year: 2014 end-page: 43 article-title: Proteome‐wide analysis and CXCL4 as a biomarker in systemic sclerosis publication-title: N Engl J Med – volume: 32 start-page: 381 year: 2014 end-page: 6 article-title: The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells [letter] publication-title: Nat Biotechnol – volume: 195 start-page: 18 year: 2018 end-page: 29 article-title: Dendritic cells in systemic sclerosis: advances from human and mice studies [review] publication-title: Immunol Lett – volume: 12 start-page: R128 year: 2010 article-title: Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis publication-title: Arthritis Res Ther – volume: 387 start-page: 2630 year: 2016 end-page: 40 article-title: Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial publication-title: Lancet – volume: 19 start-page: 1202 year: 1992 end-page: 6 article-title: Macrophage infiltration in the skin of patients with systemic sclerosis publication-title: J Rheumatol – volume: 67 start-page: 3016 year: 2015 end-page: 26 article-title: Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis publication-title: Arthritis Rheumatol – volume: 97 start-page: 41 year: 2020 end-page: 9 article-title: Transcriptome landscape of myeloid cells in human skin reveals diversity, rare populations and putative DC progenitors publication-title: J Dermatol Sci – volume: 70 start-page: 912 year: 2018 end-page: 9 article-title: Skin gene expression is prognostic for the trajectory of skin disease in patients with diffuse cutaneous systemic sclerosis publication-title: Arthritis Rheumatol – volume: 67 start-page: 3004 year: 2015 end-page: 15 article-title: A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis publication-title: Arthritis Rheumatol – volume: 154635 year: 2019 article-title: Type I interferon dysregulation in systemic sclerosis [review] publication-title: Cytokine – volume: 132 start-page: 1363 year: 2012 end-page: 73 article-title: Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies publication-title: J Invest Dermatol – volume: 36 start-page: 411 year: 2018 end-page: 20 article-title: Integrating single‐cell transcriptomic data across different conditions, technologies, and species publication-title: Nat Biotechnol – volume: 78 start-page: 1379 year: 2019 end-page: 87 article-title: Single‐cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis‐associated interstitial lung disease publication-title: Ann Rheum Dis – volume: 63 start-page: 48 year: 1995 end-page: 56 article-title: Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages publication-title: Pathobiology – volume: 178 start-page: 19 year: 2011 end-page: 25 article-title: Wound macrophages as key regulators of repair: origin, phenotype, and function [review] publication-title: Am J Pathol – volume: 97 start-page: 61 year: 2015 end-page: 9 article-title: The chemotaxis of M1 and M2 macrophages is regulated by different chemokines publication-title: J Leukoc Biol – volume: 35 start-page: 469 year: 2017 end-page: 99 article-title: Antigen‐presenting cells in the skin [review] publication-title: Annu Rev Immunol – volume: 70 start-page: 544 year: 2011 end-page: 50 article-title: dsRNA activation of endothelin‐1 and markers of vascular activation in endothelial cells and fibroblasts publication-title: Ann Rheum Dis – volume: 54 year: 2019 article-title: Proliferating SPP1/MERTK‐expressing macrophages in idiopathic pulmonary fibrosis publication-title: Eur Respir J – ident: e_1_2_7_41_1 doi: 10.1038/s41590-018-0136-9 – ident: e_1_2_7_20_1 doi: 10.1038/s41467-021-24607-6 – ident: e_1_2_7_11_1 doi: 10.1002/art.38288 – ident: e_1_2_7_19_1 doi: 10.1016/j.jid.2017.09.045 – ident: e_1_2_7_2_1 doi: 10.1016/S0140-6736(17)30933-9 – ident: e_1_2_7_25_1 doi: 10.1038/nbt.2859 – ident: e_1_2_7_24_1 doi: 10.1002/art.40455 – ident: e_1_2_7_31_1 doi: 10.1146/annurev-immunol-051116-052215 – ident: e_1_2_7_42_1 doi: 10.3389/fimmu.2019.01222 – ident: e_1_2_7_40_1 doi: 10.1038/s41467-019-09683-z – ident: e_1_2_7_43_1 doi: 10.1016/j.ajpath.2010.08.003 – ident: e_1_2_7_14_1 doi: 10.1002/art.39289 – ident: e_1_2_7_33_1 doi: 10.1038/jid.2011.472 – ident: e_1_2_7_23_1 doi: 10.1038/s41577-018-0029-z – ident: e_1_2_7_32_1 doi: 10.1084/jem.20190811 – ident: e_1_2_7_12_1 doi: 10.1002/art.39287 – ident: e_1_2_7_39_1 doi: 10.1136/annrheumdis-2018-214865 – volume: 154635 year: 2019 ident: e_1_2_7_30_1 article-title: Type I interferon dysregulation in systemic sclerosis [review] publication-title: Cytokine – ident: e_1_2_7_8_1 doi: 10.1186/ar3066 – ident: e_1_2_7_15_1 doi: 10.1126/scitranslmed.aam8458 – ident: e_1_2_7_13_1 doi: 10.1371/journal.pone.0002696 – ident: e_1_2_7_36_1 doi: 10.1038/jid.2010.200 – ident: e_1_2_7_22_1 doi: 10.1038/s41592-019-0619-0 – ident: e_1_2_7_4_1 doi: 10.1016/j.imlet.2017.11.003 – ident: e_1_2_7_27_1 doi: 10.1111/imm.12888 – ident: e_1_2_7_38_1 doi: 10.1183/13993003.02441-2018 – ident: e_1_2_7_17_1 doi: 10.1056/NEJMoa1114576 – ident: e_1_2_7_3_1 doi: 10.1007/s11926-019-0831-z – ident: e_1_2_7_35_1 doi: 10.1136/ard.2010.132464 – ident: e_1_2_7_26_1 doi: 10.1038/nbt.4096 – ident: e_1_2_7_7_1 doi: 10.1002/art.22382 – ident: e_1_2_7_16_1 doi: 10.1371/journal.pone.0001452 – ident: e_1_2_7_21_1 doi: 10.1126/science.aah4573 – ident: e_1_2_7_10_1 doi: 10.1189/jlb.1A0314-170R – volume: 19 start-page: 1202 year: 1992 ident: e_1_2_7_5_1 article-title: Macrophage infiltration in the skin of patients with systemic sclerosis publication-title: J Rheumatol – ident: e_1_2_7_29_1 doi: 10.1172/jci.insight.98850 – ident: e_1_2_7_6_1 doi: 10.1159/000163933 – ident: e_1_2_7_9_1 doi: 10.1136/annrheumdis-2012-202814 – ident: e_1_2_7_28_1 doi: 10.1186/ar4598 – ident: e_1_2_7_18_1 doi: 10.1016/j.jdermsci.2019.11.012 – ident: e_1_2_7_34_1 doi: 10.1089/wound.2017.0732 – ident: e_1_2_7_37_1 doi: 10.1016/S0140-6736(16)00232-4 – reference: 35644033 - Arthritis Rheumatol. 2022 Oct;74(10):1721-1722 |
SSID | ssj0000970605 |
Score | 2.578394 |
Snippet | Objective
In this study, we sought a comprehensive understanding of myeloid cell types driving fibrosis in diffuse cutaneous systemic sclerosis (dcSSc) skin.... In this study, we sought a comprehensive understanding of myeloid cell types driving fibrosis in diffuse cutaneous systemic sclerosis (dcSSc) skin. We analyzed... ObjectiveIn this study, we sought a comprehensive understanding of myeloid cell types driving fibrosis in diffuse cutaneous systemic sclerosis (dcSSc)... In this study, we sought a comprehensive understanding of myeloid cell types driving fibrosis in diffuse cutaneous systemic sclerosis (dcSSc) skin.OBJECTIVEIn... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 329 |
SubjectTerms | Biopsy CC chemokine receptors CCR1 protein Cell activation Chemokines Clustering Dendritic cells Dendritic Cells - immunology Dendritic structure Embedding Fibrosis Ficolins Gene sequencing Humans Immune system Immunofluorescence Innate immunity Lectins - biosynthesis Lectins - immunology Lymphocytes B Macrophages Macrophages - immunology Macrophages - metabolism MARCO protein Monocytes Monocytes - immunology Monocytes - metabolism Myeloid cells Pathogenesis Progenitor cells Receptors Receptors, IgG - biosynthesis Receptors, IgG - immunology Scleroderma Scleroderma, Diffuse - immunology Severity of Illness Index Skin diseases Systemic sclerosis Transcription Transcriptomes |
Title | Expansion of Fcγ Receptor IIIa–Positive Macrophages, Ficolin 1–Positive Monocyte‐Derived Dendritic Cells, and Plasmacytoid Dendritic Cells Associated With Severe Skin Disease in Systemic Sclerosis |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fart.41813 https://www.ncbi.nlm.nih.gov/pubmed/34042322 https://www.proquest.com/docview/2622955591 https://www.proquest.com/docview/2533318496 |
Volume | 74 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ZbtNAFB21RUK8IHYCBQ0VlZBSB3vGS_xY0kRJaUulpiI8WZ7JRIkIdpQFAU_9BCQ-hc9A4iP6JdxZvISE9cUaOeMt93juueM75yL01A5iQbkIrXhAAstl1LFi7jErkNqbfl8QEci1w8cnfvvcPex5vY3NnVLW0mLOavzT2nUl_2NV2Ad2latk_8Gy-UlhB7TBvrAFC8P2r2zc_ADv8sxQvhbfbTR3X1DJBMUEQulqp9OJs2QGeqqys3SpoWk6GcI4okzYklAYJVVnTc80SfnHucgTIg7god4Lmbqc9FWJhGpDjMezLAP0FJj4uxiOSEcrfXIcwOGv5dzvmYC_W1Rl8S8pASq_Esm5F62gDkedwbOCBx_NyvR5fzofKhUmhdjpUCyAcGsVKWDK7ZSlb4VZQHZYK01y9BbCrKcvZirYSH2KAmfNi0zodKoLTWrNBVNaXI2KZl79zag8TwIhtr2Uc_Ln0bgYeYFl-hZQW320KO0jtld2HbrAkHlFSMkPUPOEmlJQre214q20-i3Ap-YC0aKFS87SEE5eRa3zo6Oo2-x1N9EVAqGQrNJx0HmZzyPaodQ_8lQNRXPXmYCWTZ7n516mXSux1HJoprhV9wa6boIivK8RfhNtiOQWunps0j5uo2850HE6wC3-_SvOQI4lyC8vvmSgxSV472EDbuws9TCwvrz4bACNc7BiBdY9DHDGZTj_3AMXcMYSzljDGUs4YwNnDM0MzjiH8x103mp2G23LVCGxOK3XqUWZkKqdQK0dLwj80GO0LgIWxqEbBB7QfyYVkoIBY-Ar_RjiIWjEMnvaBQLKQ3oXbSVpIu4jTHzBOAQIfp8zt-_FLPTrJOR1xw78gQgHFfQsM1LEjUS_rBQzjrS4OInAnpGyZwXt5F0nWpdmXaftzNKRGbZmEfEJCT3PC50KepL_DE5FfimME5EuoA8EgeDs3dCvoHsaIflVqCtT6QiBm1WQ-fXlIwjJVePB7-_jIbpWvLDbaGs-XYhHQPXn7LHC-g8h7wH- |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Expansion+of+Fc%CE%B3+Receptor+IIIa%E2%80%93Positive+Macrophages%2C+Ficolin+1%E2%80%93Positive+Monocyte%E2%80%90Derived+Dendritic+Cells%2C+and+Plasmacytoid+Dendritic+Cells+Associated+With+Severe+Skin+Disease+in+Systemic+Sclerosis&rft.jtitle=Arthritis+%26+rheumatology+%28Hoboken%2C+N.J.%29&rft.au=Xue%2C+Dan&rft.au=Tabib%2C+Tracy&rft.au=Morse%2C+Christina&rft.au=Yang%2C+Yi&rft.date=2022-02-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=2326-5191&rft.eissn=2326-5205&rft.volume=74&rft.issue=2&rft.spage=329&rft.epage=341&rft_id=info:doi/10.1002%2Fart.41813&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2326-5191&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2326-5191&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2326-5191&client=summon |